Focused On-demand Library for Dual specificity protein phosphatase 4

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q13115

UPID:
DUS4_HUMAN

ALTERNATIVE NAMES:
Dual specificity protein phosphatase hVH2; Mitogen-activated protein kinase phosphatase 2

ALTERNATIVE UPACC:
Q13115; B2RBU5; D3DSU4; G5E930; Q13524

BACKGROUND:
The protein Dual specificity protein phosphatase 4, with alternative names such as Dual specificity protein phosphatase hVH2 and Mitogen-activated protein kinase phosphatase 2, is essential for the regulation of mitogenic signal transduction. It achieves this by dephosphorylating both Thr and Tyr residues on MAP kinases ERK1 and ERK2, thereby playing a key role in cell proliferation and differentiation.

THERAPEUTIC SIGNIFICANCE:
The exploration of Dual specificity protein phosphatase 4's function in cellular signaling pathways presents a unique opportunity for the development of novel therapeutic approaches. By targeting this protein, new strategies for treating diseases with underlying signaling dysregulation could be unveiled.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.